Stable isotope methodology for kinetic studies of interconversion of cortisol and cortisone in a human subject

Steroids

Volumn 63, Issue 3, 1998, Pages 122-129

  Kasuya, Yasuji ^a   Ishimaru, Hiromasa ^a   Shibasaki, Hiromi ^a   Furuta, Takashi ^a  

^a TOKYO UNIVERSITY OF PHARMACY AND LIFE SCIENCES   (Japan)

Author keywords

Deuterium labeled cortisol; Deuterium labeled cortisone; Gas chromatography mass spectrometry; Kinetic analysis

Indexed keywords

CORTISONE; DEUTERIUM; HYDROCORTISONE;

ADULT; AREA UNDER THE CURVE; ARTICLE; CHEMICAL REACTION KINETICS; DOSE RESPONSE; GAS CHROMATOGRAPHY; HUMAN; HUMAN CELL; HUMAN EXPERIMENT; HUMAN TISSUE; HYDROCORTISONE BLOOD LEVEL; ISOTOPE LABELING; MALE; MASS SPECTROMETRY; NORMAL HUMAN; ORAL DRUG ADMINISTRATION; STEROID METABOLISM;

ADMINISTRATION, ORAL; ADULT; CORTISONE; DEUTERIUM; GAS CHROMATOGRAPHY-MASS SPECTROMETRY; HUMANS; HYDROCORTISONE; KINETICS; MALE;

EID: 0032031067     PISSN: 0039128X     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0039-128X(97)00102-5     Document Type: Article

References (32)

1. Murphy BEP. Ontogeny of cortisol-cortisone interconversion in human tissues A role for cortisone in human fetal development . J Steroid Biochem. 14:1981;811-817.
2. Funder JW, Pearce PT, Smith RA, Smith I. Mineralocorticoid action Target tissue specificity is enzyme, not receptor, mediated . Science (Washington DC). 242:1988;583-585.
3. Edwards CRW, Benediktson R, Lindsay RS, Seckl JR. 11β-Hydroxysteroid dehydrogenase Key enzymes in determining tissue-specific glucocorticoid effects . Steroids. 61:1996;263-269.
4. White PC, Mune T, Agarwal K. Functional studies of 11β-hydroxysteroid dehydrogenase. Steroids. 60:1995;65-68.
5. Stewart PM, Murry BA, Mason JI. Human kidney 11β-hydroxysteroid dehydrogenase is a high affinity nicotinamide adenine dinucleotide-dependent enzyme and differs from the cloned type I isoform. J Clin Edocrinol Metab. 80:1944;2203-2209.
6. Krozowski ZS, Provencher PH, Smith RE, Obeyesekere VR, Mercer WR, Albiston AL. Isozymes of 11β-hydroxysteroid dehydrogenase Which enzyme endows mineralocorticoid specificity? Steroids. 59:1994;116-119.
7. Krozowski ZS, Maguire JA, Stein-Oakley AN, Dowling J, Smith RE, Andrews RK. Immunohistochemical localization of the 11β-hydroxysteroid dehydrogenase type II enzyme in human kidney and placenta. J Clin Endocrinol Metab. 79:1995;480-484.
8. Walker BR, Stewart PM, Shackleton CHL, Padfield PL, Edwards CRW. Deficient inactivation of cortisol by 11β-hydroxysteroid dehydrogenase in essential hypertension. Clin Edocrinol. 39:1993;221-227.
9. Stewart PM, Krozowski ZS, Gupta A, Milford DW, Howie AJ, Sheppard MC, Whorwood CB. Hypertension in the syndrome of apparent mineralocorticoid excess due to mutation of the 11β-hydroxysteroid dehydrogenase type 2 gene. Lancet. 347:1996;88-91.
10. Agarwal AK, Tusie-Luna M-T, Monder C, White PC. Expression of 11β-hydroxysteroid dehydrogenase using recombinant vaccinia virus. Mol Endocrinol. 4:1990;1827-1832.
11. Frey FJ, Escher G, Frey BM. Pharmacology of 11β-hydroxysteroid dehydrogenase. Steroids. 59:1994;74-79.
12. Stewart PM, Whorwood CB. 11β-Hydroxysteroid dehydrogenase activity and corticosteroid hormone action. Steroids. 59:1994;90-95.
13. Kasuya Y, Iwano M, Shibasaki H, Furuta T. Pharmacokinetic studies of cortisol after oral administration of deuterium-labelled cortisol to a normal human subject. J Mass Spectrum Rapid Comm Mass Spectrom. 1995;s29-s34.
14. Minagawa K, Furuta T, Kasuya Y, Fujino A, Avery MA, Tanabe M. Total synthesis of cortisol application to selective deuteriation at C-1 and C-19 . J Chem Soc Perkin Trans 1. 1988;587-591.
15. Shibasaki H, Furuta T, Kasuya Y. Stereochemical aspects in the enantioselective synthesis of cortisone by the indan synthon method. Steroids. 57:1992;325-327.
16. Shibasaki H, Furuta T, Kasuya Y. Simultaneous determination of cortisol and cortisone in human plasma by stable-isotope dilution mass spectrometry. J Chromatogr. 576:1992;47-52.
17. Shibasaki H, Furuta T, Kasuya Y, Okabe T, Katoh T, Kogo T, Hirayama T. Diurnal rhythm in the plasma concentration of cortisol in paediatric patients with orthostatic dysregulation. Biomed Environ Mass Spectrom. 19:1990;225-229.
18. Scavo D, Cugini P, Lascio GD. The metabolic clearance rate of cortisol in normal subjects and in various disease states. J Nuc Med Allied Sci. 22:1978;113-123.
19. Dorfman RI, Unger F. Metabolism of Steroid Hormones. 1965;605 Academic Press, New York.
20. Van Der Straeten M, Vermeulen A, Orie N. The determination of cortisol and cortisone production rates by an isotope dilution method. Acta Endocrinol. 43:1963;430-438.
21. Hellman L, Nakada F, Zumoff B, Fukushima D, Bradlow HL, Gallagher TF. Renal capture and oxidation of cortisol in man. J Clin Edocrinol Metab. 33:1971;52-62.
22. Walker BR, Campbell JC, Fraser R, Stewart PM, Edwards CRW. Mineralocorticoid excess and inhibition of 11β-hydroxysteroid dehydrogenase in patients with ectopic ACTH syndrome. Clin Edocrinol (Oxf). 37:1992;483-492.
23. Monder C, Shackleton CHL. 11β-Hydroxysteroid dehydrogenase Fact or fancy? Steroids. 44:1984;383-417.
24. Jenkins JS, Sampson PA. Conversion of cortisone to cortisol and prednisone to prednisolone. Br Med J. 2:1967;205-207.
25. Barbato AL, Landau RL. Serum cortisol appearance-disappearance in adrenal insufficiency after oral cortisone acetate. Acta Edocrinol. 84:1977;600-604.
26. Fariss RL, Hane S, Shinsako J, Orsham PH. Comparison of absorption of cortisone acetate and hydrocortisone hemisuccinate. J Clin Edocrinol Metab. 33:1978;52-62.
27. Colburn WA, Disanto AR, Stubbs SS, Monovich RE, Desante KA. Pharmacokinetic interpretation of plasma cortisol and cortisone concentrations following a single oral administration of cortisone acetate to human subjects. J Clin Pharmacol. 20:1980;428-436.
28. Aanderud S, Myking OL. Plasma cortisol concentrations after oral substitution of cortisone in the fasting and non-fasting state. Acta Med Scan. 210:1981;157-161.
29. Heazelwood VJ, Galligan JP, Cannell GR, Bochner F, Mortimer RH. Plasma cortisol delivery from oral cortisol and cortisone acetate relative bioavailability . Br J Clin Pharmacol. 17:1984;55-59.
30. Mantero F, Palermo M, Petrelli MD, Tedde R, Stewart PM, Shack-leton CHL. Apparent mineralocorticoid excess Type I and type II . Steroids. 61:1996;193-196.
31. Funder JW. Apparent mineralocorticoid excess. Endocrinol Metab Clin North Am. 24:1995;613-621.
32. Stewart PM, Corrie JET, Shackleton CHL, Edwards CRW. Syndrome of apparent mineralocorticoid excess A defect in the cortisol-cortisone shuttle . J Clin Invest. 82:1988;340-349.